‘Record high’ two million people at type II diabetes risk
There are 1,969,610 people registered with a GP who have non-diabetic hyperglycaemia, a condition which puts people at high risk of type II.
Read More
Tag: type II diabetes
Invokana bags FDA approval
The treatment has been approved to reduce the risk of hospitalisation for heart failure in certain patients with type II diabetes.
Read More
Tresiba lowers risk of hypos in type II diabetes
Tresiba significantly reduced the rate of severe hypoglycaemia by 80% and nocturnal symptomatic hypoglycaemia by 37%.
Read More
Brilinta reduces CV events but increases bleeding
The drug reduced the relative risk for the composite of cardiovascular death, heart attack, or stroke by 10% compared with aspirin alone.
Read More
AZ’ Farxiga shows 47% reduction in kidney function decline
The SGLT2 inhibitor was evaluated in 17,160 patients with type II diabetes.
Read More
NHS to launch new online type II diabetes support
The new online portal will offer people with type II diabetes evidence-based information and support.
Read More
Novo Nordisk files for EU approval of Ozempic in type II diabetes
Patients treated with oral semaglutide demonstrated greater HbA1c reductions and weight loss.
Read More
Data show J&J’s Invokana may slow or prevent CKD in diabetes patients
The data provides the first significant update in nearly 20 years regarding slowing the progression of CKD in patients with type II diabetes.
Read More
NHS to double diabetes prevention programme after patients lose 60,000kg collectively
The programme is set to include around 200,000 people annually.
Read More
J&J submits sNDA for Invokana after premature end to clinical trial
If approved, the drug will be the only therapy in nearly 20 years to reduce the risk of end-stage kidney disease.
Read More
NICE recommendation for Steglatro in type II diabetes
MSD’s SGLT-2 inhibitor Steglatro will be available for some patients with type II diabetes on the NHS in England and Wales.
Read More
Study shows reduced hypoglycaemia after switch to Tresiba
Novo Nordisk’s Tresiba has been found to be efficient in treating diabetes compared to other basal insulins.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
